“Previously, patients could only use Enhertu by participating in clinical trials conducted in tertiary general hospitals. Current approval in South Korea will provide a new treatment option for patients with HER2 mutant metastatic non-small cell lung cancer (NSCLC). Brain metastasis is common in lung cancer patients. Because Enhertu demonstrated a response rate of 50% in patients with brain metastasis, it is clinically significant.”

During a recent meeting with Daily Pharm, Ahn Myung Ju, Professor of the Division of Hematology-oncology in the Department of Medicine at Samsung Medical Center, highly regarded the clinical value of Enhertu (ingredient: trastuzumab deruxtecan).

Enhertu, an